Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational oral treatment for Alzheimer’s disease, in the second half of this year, the company announced. If successful, results of these studies in patients with mild-to-moderate disease will support a request for simufilam’s approval. “For over 10 years we’ve been doing basic research and early drug development with simufilam. We are excited to finally advance simufilam into pivotal Phase…
You must be logged in to read/download the full post.
The post Pivotal Phase 3 Trials of Oral Simufilam Planned for Year’s End appeared first on BioNewsFeeds.